Aristotle Capital Boston LLC Lowers Stock Position in Haemonetics Corporation $HAE

Aristotle Capital Boston LLC lowered its position in Haemonetics Corporation (NYSE:HAE) by 8.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 370,308 shares of the medical instruments supplier’s stock after selling 33,854 shares during the period. Haemonetics comprises about 1.6% of Aristotle Capital Boston LLC’s portfolio, making the stock its 11th largest position. Aristotle Capital Boston LLC’s holdings in Haemonetics were worth $29,680,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Kemnay Advisory Services Inc. bought a new position in Haemonetics during the fourth quarter valued at about $26,000. True Wealth Design LLC grew its position in Haemonetics by 6,700.0% during the fourth quarter. True Wealth Design LLC now owns 340 shares of the medical instruments supplier’s stock valued at $27,000 after buying an additional 335 shares during the period. Leonteq Securities AG bought a new position in Haemonetics during the fourth quarter valued at about $30,000. EverSource Wealth Advisors LLC grew its position in Haemonetics by 2,640.0% during the second quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier’s stock valued at $31,000 after buying an additional 396 shares during the period. Finally, Kestra Advisory Services LLC bought a new position in Haemonetics during the fourth quarter valued at about $34,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the stock. Mizuho increased their price target on shares of Haemonetics from $70.00 to $85.00 and gave the company an “outperform” rating in a research report on Monday. Bank of America upgraded shares of Haemonetics from a “neutral” rating to a “buy” rating and increased their price target for the company from $72.00 to $80.00 in a research report on Friday, May 22nd. Robert W. Baird set a $67.00 price target on shares of Haemonetics in a research report on Friday, May 8th. JPMorgan Chase & Co. reduced their price target on shares of Haemonetics from $74.00 to $62.00 and set a “neutral” rating for the company in a research report on Friday, May 8th. Finally, Citigroup increased their price target on shares of Haemonetics from $64.00 to $70.00 and gave the company a “neutral” rating in a research report on Thursday, May 28th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $78.33.

Haemonetics Price Performance

Shares of NYSE:HAE opened at $72.78 on Thursday. The company has a quick ratio of 1.87, a current ratio of 2.95 and a debt-to-equity ratio of 1.53. The firm has a market capitalization of $3.31 billion, a PE ratio of 36.03, a P/E/G ratio of 1.50 and a beta of 0.56. Haemonetics Corporation has a twelve month low of $47.31 and a twelve month high of $87.32. The company has a 50-day moving average price of $63.31 and a two-hundred day moving average price of $67.15.

Haemonetics (NYSE:HAE) last announced its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $1.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.28 by $0.01. Haemonetics had a net margin of 7.29% and a return on equity of 27.30%. The firm had revenue of $346.35 million for the quarter, compared to the consensus estimate of $336.83 million. During the same period in the prior year, the firm posted $1.24 earnings per share. The company’s revenue for the quarter was up 4.8% on a year-over-year basis. Haemonetics has set its FY 2027 guidance at 5.258-5.307 EPS. Equities analysts forecast that Haemonetics Corporation will post 5.22 EPS for the current year.

About Haemonetics

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.